Foghorn therapeutics to participate in the bank of america 2022 precision oncology conference

Cambridge, mass., sept. 27, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the company will participate in the bank of america 2022 precision oncology conference, which will be held virtually on october 3rd, 2022. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking